These are extraordinary times – for the entire world, but also for us as a company. We are looking back on a year unlike any we have experienced before. A year of huge challenges in both medical and economic terms. Challenges that to a great extent are still with us. Just how we have dealt with and will continue to deal with these challenges – the successes we have had and what we are going to do to remain successful – is what I intend to convey to you below.
Fresenius is making important contributions to high-quality and affordable health care worldwide during the COVID-19 pandemic. In this way, we are standing by our patients – and living up to our social responsibility.
We provide here a brief overview of the implications of COVID-19 on Fresenius and our individual business segments in 2020.
We are committed to responsible and sustainable management as part of our corporate culture and day-to-day business practice. Only by doing so can we be perceived as a trustworthy and reliable partner in the health care sector.Sustainability Report
FY/19: €35,409 m
FY/19: €4,688 m
Dec. 31, 2019: 294,134
Net Income 3,4
FY/19: €1,879 m
Earnings per Share 3,4
1 In constant currency
3 Before special items
4 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Annual Report 2020 (IFRS)(PDF, 10 MB)
Financial Statements 2020 (HGB)(PDF, 2 MB)
Factsheet FY/20(PDF, 452 KB)
Investor Relations Company Presentation(PDF, 5 MB)
At a Glance(PDF, 657 KB)
Annual Report 2019 (IFRS)(PDF, 9 MB)
Financial Statements 2019 (HGB)(PDF, 3 MB)
Annual Report 2018 (IFRS)(PDF, 5 MB)
Financial Statements 2018 (HGB)(PDF, 1 MB)